{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:16:48Z","timestamp":1760267808650},"reference-count":54,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,29]]},"DOI":"10.7759\/cureus.29752","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T16:54:06Z","timestamp":1664470446000},"source":"Crossref","is-referenced-by-count":5,"title":["Prevalence of Myositis-Specific Autoantibodies and Myositis-Associated Autoantibodies in COVID-19 Patients: A Pilot Study and Literature Review"],"prefix":"10.7759","author":[{"given":"Isaac","family":"Swartzman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan  J","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Toner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raminder","family":"Grover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmanan","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori  E","family":"Ullman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1573397116666201029155856","article-title":"COVID-19 and autoimmune diseases: a systematic review of reported cases","volume":"17","author":"Saad MA","year":"2021","unstructured":"Saad MA, Alfishawy M, Nassar M, Mohamed M, Esene IN, Elbendary A. COVID-19 and autoimmune diseases: a systematic review of reported cases. Curr Rheumatol Rev. 2021, 17:193-204. 10.2174\/1573397116666201029155856","journal-title":"Curr Rheumatol Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2020.05.003","article-title":"The cytokine storm in COVID-19: an overview of the involvement of the chemokine\/chemokine-receptor system","volume":"53","author":"Coperchini F","year":"2020","unstructured":"Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine\/chemokine-receptor system. Cytokine Growth Factor Rev. 2020, 53:25-32. 10.1016\/j.cytogfr.2020.05.003","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2021.1898790","article-title":"Immune dysregulation and system pathology in COVID-19","volume":"12","author":"Jamal M","year":"2021","unstructured":"Jamal M, Bangash HI, Habiba M, et al.. Immune dysregulation and system pathology in COVID-19. Virulence. 2021, 12:918-36. 10.1080\/21505594.2021.1898790","journal-title":"Virulence"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102597","article-title":"Covid-19 and autoimmunity","volume":"19","author":"Ehrenfeld M","year":"2020","unstructured":"Ehrenfeld M, Tincani A, Andreoli L, et al.. Covid-19 and autoimmunity. Autoimmun Rev. 2020, 19:102597. 10.1016\/j.autrev.2020.102597","journal-title":"Autoimmun Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05334-7","article-title":"COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series","volume":"39","author":"Ferri C","year":"2020","unstructured":"Ferri C, Giuggioli D, Raimondo V, et al.. COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol. 2020, 39:3195-204. 10.1007\/s10067-020-05334-7","journal-title":"Clin Rheumatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.15167\/2421-4248\/jpmh2020.61.3.1530","article-title":"Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis","volume":"61","author":"Alimohamadi Y","year":"2020","unstructured":"Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020, 61:E304-12. 10.15167\/2421-4248\/jpmh2020.61.3.1530","journal-title":"J Prev Med Hyg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01023-9","article-title":"COVID-19 and myositis: what we know so far","volume":"23","author":"Saud A","year":"2021","unstructured":"Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and myositis: what we know so far. Curr Rheumatol Rep. 2021, 23:63. 10.1007\/s11926-021-01023-9","journal-title":"Curr Rheumatol Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.2004","article-title":"Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died","volume":"78","author":"Aschman T","year":"2021","unstructured":"Aschman T, Schneider J, Greuel S, et al.. Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died. JAMA Neurol. 2021, 78:948-60. 10.1001\/jamaneurol.2021.2004","journal-title":"JAMA Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25509-3","article-title":"New-onset IgG autoantibodies in hospitalized patients with COVID-19","volume":"12","author":"Chang SE","year":"2021","unstructured":"Chang SE, Feng A, Meng W, et al.. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021, 12:5417. 10.1038\/s41467-021-25509-3","journal-title":"Nat Commun"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S312090","article-title":"Prevalence and characteristics of rheumatoid-associated autoantibodies in patients with COVID-19","volume":"14","author":"Xu C","year":"2021","unstructured":"Xu C, Fan J, Luo Y, et al.. Prevalence and characteristics of rheumatoid-associated autoantibodies in patients with COVID-19. J Inflamm Res. 2021, 14:3123-8. 10.2147\/JIR.S312090","journal-title":"J Inflamm Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh M","year":"2017","unstructured":"Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2017, 52:1-19. 10.1007\/s12016-015-8510-y","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.747116\u00a0","article-title":"COVID-19 disease and dermatomyositis: a mini-review","volume":"12","author":"Qian J","year":"2021","unstructured":"Qian J, Xu H. COVID-19 disease and dermatomyositis: a mini-review. Front Immunol. 2021, 12:747116. 10.3389\/fimmu.2021.747116\u00a0","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.791348","article-title":"Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study","volume":"12","author":"Wang G","year":"2021","unstructured":"Wang G, Wang Q, Wang Y, et al.. Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. Front Immunol. 2021, 12:791348. 10.3389\/fimmu.2021.791348","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2022.37.e32\u00a0","article-title":"Dermatomyositis following BNT162b2 mRNA COVID-19 vaccination","volume":"37","author":"Gouda W","year":"2022","unstructured":"Gouda W, Albasri A, Alsaqabi F, et al.. Dermatomyositis following BNT162b2 mRNA COVID-19 vaccination. J Korean Med Sci. 2022, 37:5. 10.3346\/jkms.2022.37.e32\u00a0","journal-title":"J Korean Med Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202011_23857","article-title":"Case report of COVID-19 in an elderly patient: could SARS-CoV2 trigger myositis?","volume":"24","author":"Sacchi MC","year":"2020","unstructured":"Sacchi MC, Tamiazzo S, Lauritano EC, Bonometti R. Case report of COVID-19 in an elderly patient: could SARS-CoV2 trigger myositis?. Eur Rev Med Pharmacol Sci. 2020, 24:11960-3. 10.26355\/eurrev_202011_23857","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15716\u00a0","article-title":"Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis","volume":"8","author":"Li L","year":"2017","unstructured":"Li L, Wang Q, Yang F, et al.. Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis. Oncotarget. 2017, 8:26552-64. 10.18632\/oncotarget.15716\u00a0","journal-title":"Oncotarget"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato S","year":"2009","unstructured":"Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, Kuwana M. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009, 60:2193-200. 10.1002\/art.24621","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono T","year":"2014","unstructured":"Gono T, Kaneko H, Kawaguchi Y, et al.. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford). 2014, 53:2196-203. 10.1093\/rheumatology\/keu258","journal-title":"Rheumatology (Oxford)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00979","article-title":"The roles of TIF1\u03b3 in cancer","volume":"9","author":"Yu C","year":"2019","unstructured":"Yu C, Ding Z, Liang H, Zhang B, Chen X. The roles of TIF1\u03b3 in cancer. Front Oncol. 2019, 9:979. 10.3389\/fonc.2019.00979","journal-title":"Front Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel161","article-title":"Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy","volume":"46","author":"Kaji K","year":"2007","unstructured":"Kaji K, Fujimoto M, Hasegawa M, et al.. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford). 2007, 46:25-8. 10.1093\/rheumatology\/kel161","journal-title":"Rheumatology (Oxford)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068502","article-title":"The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis","volume":"66","author":"Chinoy H","year":"2007","unstructured":"Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007, 66:1345-9. 10.1136\/ard.2006.068502","journal-title":"Ann Rheum Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/art.22164\u00a0","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff I","year":"2006","unstructured":"Targoff I, Mamyrova G, Trieu EP, et al.. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006, 54:3682-9. 10.1002\/art.22164\u00a0","journal-title":"Arthritis Rheum"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.17161\/rrnmf.v1i3.13719","article-title":"Rhabdomyolysis and COVID-19 infection: is it due to statin use or anti-TIF1-y antibodies?","volume":"1","author":"Mantilla E","year":"2020","unstructured":"Mantilla E, Pasnoor M, Dimachkie M. Rhabdomyolysis and COVID-19 infection: is it due to statin use or anti-TIF1-y antibodies?. RRNMF Neuromuscul J. 2020, 1:22-5. 10.17161\/rrnmf.v1i3.13719","journal-title":"RRNMF Neuromuscul J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/ar147\u00a0","article-title":"The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma","volume":"3","author":"Brouwer R","year":"2001","unstructured":"Brouwer R, Pruijn GJ, van Venrooij WJ. The human exosome: an autoantigenic complex of exoribonucleases in myositis and scleroderma. Arthritis Res. 2001, 3:102-6. 10.1186\/ar147\u00a0","journal-title":"Arthritis Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/ar2614","article-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","volume":"11","author":"Hanke K","year":"2009","unstructured":"Hanke K, Br\u00fcckner CS, D\u00e4hnrich C, et al.. Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients. Arthritis Res Ther. 2009, 11:R22. 10.1186\/ar2614","journal-title":"Arthritis Res Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/art.20056\u00a0","article-title":"PM-Scl-75 is the main autoantigen in patients with the polymyositis\/scleroderma overlap syndrome","volume":"50","author":"Raijmakers R","year":"2004","unstructured":"Raijmakers R, Renz M, Wiemann C, et al.. PM-Scl-75 is the main autoantigen in patients with the polymyositis\/scleroderma overlap syndrome. Arthritis Rheum. 2004, 50:565-9. 10.1002\/art.20056\u00a0","journal-title":"Arthritis Rheum"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686699","article-title":"Case report: systemic sclerosis after COVID-19 infection","volume":"12","author":"Fineschi S","year":"2021","unstructured":"Fineschi S. Case report: systemic sclerosis after COVID-19 infection. Front Immunol. 2021, 12:686699. 10.3389\/fimmu.2021.686699","journal-title":"Front Immunol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1097\/CPM.0000000000000171","article-title":"The diagnosis and treatment of antisynthetase syndrome","volume":"23","author":"Witt LJ","year":"2016","unstructured":"Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med. 2016, 23:218-26. 10.1097\/CPM.0000000000000171","journal-title":"Clin Pulm Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-021-00171-x\u00a0\u00a0","article-title":"The relevance of anti-Jo-1 autoantibodies in patients with definite dermatomyositis","volume":"1186","author":"de Andrade VP","year":"2021","unstructured":"de Andrade VP, De Souza FH, Behrens Pinto GL, et al.. The relevance of anti-Jo-1 autoantibodies in patients with definite dermatomyositis. Adv Rheumatol. 2021, 1186:10.1186\/s42358-021-00171-x\u00a0\u00a0","journal-title":"Adv Rheumatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2021.111836","article-title":"COVID-19 vaccination-associated anti-Jo-1 syndrome","volume":"59","author":"Gupta K","year":"2021","unstructured":"Gupta K, Sharma GS, Kumar A. COVID-19 vaccination-associated anti-Jo-1 syndrome. Reumatologia. 2021, 59:420-2. 10.5114\/reum.2021.111836","journal-title":"Reumatologia"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1126\/science.1196473","article-title":"The crystal structure of the signal recognition particle in complex with its receptor","volume":"331","author":"Ataide SF","year":"2011","unstructured":"Ataide SF, Schmitz N, Shen K, Ke A, Shan SO, Doudna JA, Ban N. The crystal structure of the signal recognition particle in complex with its receptor. Science. 2011, 331:881-6. 10.1126\/science.1196473","journal-title":"Science"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330908","article-title":"Antibody to signal recognition particle in polymyositis","volume":"33","author":"Targoff IN","year":"1990","unstructured":"Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990, 33:1361-70. 10.1002\/art.1780330908","journal-title":"Arthritis Rheum"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.052191","article-title":"Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy","volume":"65","author":"Hengstman GJ","year":"2006","unstructured":"Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al.. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006, 65:1635-8. 10.1136\/ard.2006.052191","journal-title":"Ann Rheum Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez I","year":"2018","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018, 20:21. 10.1007\/s11926-018-0732-6","journal-title":"Curr Rheumatol Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27483","article-title":"Immune-mediated necrotizing myopathy after BNT162b2 vaccination in a patient with antibodies against receptor-binding domain of SARS-CoV-2 and signal recognition particle","volume":"65","author":"Dodig D","year":"2022","unstructured":"Dodig D, Fritzler MJ, Naraghi A, Tarnopolsky MA, Lu JQ. Immune-mediated necrotizing myopathy after BNT162b2 vaccination in a patient with antibodies against receptor-binding domain of SARS-CoV-2 and signal recognition particle. Muscle Nerve. 2022, 65:E11-3. 10.1002\/mus.27483","journal-title":"Muscle Nerve"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20979","article-title":"COVID-19 vaccine-induced pneumonitis, myositis and myopericarditis","volume":"14","author":"Farooq M","year":"2022","unstructured":"Farooq M, Mohammed Y, Zafar M, Dharmasena D, Rana UI, Kankam O. COVID-19 vaccine-induced pneumonitis, myositis and myopericarditis. Cureus. 2022, 14:e20979. 10.7759\/cureus.20979","journal-title":"Cureus"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.934399\u00a0","article-title":"Myocarditis, pulmonary hemorrhage, and extensive myositis with rhabdomyolysis 12 days after first dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: a case report","volume":"23","author":"Al-Rasbi S","year":"2022","unstructured":"Al-Rasbi S, Al-Maqbali JS, Al-Farsi R, et al.. Myocarditis, pulmonary hemorrhage, and extensive myositis with rhabdomyolysis 12 days after first dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine: a case report. Am J Case Rep. 2022, 23:934399. 10.12659\/AJCR.934399\u00a0","journal-title":"Am J Case Rep"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27175","article-title":"AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: a case report","volume":"93","author":"Capassoni M","year":"2021","unstructured":"Capassoni M, Ketabchi S, Cassisa A, Caramelli R, Molinu AA, Galluccio F, Guiducci S. AstraZeneca (AZD1222) COVID-19 vaccine-associated adverse drug event: a case report. J Med Virol. 2021, 93:5718-20. 10.1002\/jmv.27175","journal-title":"J Med Virol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-022-03266-1","article-title":"Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: two case reports","volume":"16","author":"Vutipongsatorn K","year":"2022","unstructured":"Vutipongsatorn K, Isaacs A, Farah Z. Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: two case reports. J Med Case Rep. 2022, 16:57. 10.1186\/s13256-022-03266-1","journal-title":"J Med Case Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2020.07.003","article-title":"Myopathy associated with severe SARS-CoV-2 infection","volume":"35","author":"Abenza Abild\u00faa MJ","year":"2020","unstructured":"Abenza Abild\u00faa MJ, Ram\u00edrez Prieto MT, Moreno Zabaleta R, Algarra Lucas C, P\u00e9rez L\u00f3pez C. Myopathy associated with severe SARS-CoV-2 infection. Neurologia (Engl Ed). 2020, 35:706-8. 10.1016\/j.nrl.2020.07.003","journal-title":"Neurologia (Engl Ed)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031085","article-title":"Covid-19-associated myopathy caused by type I interferonopathy","volume":"383","author":"Manzano GS","year":"2020","unstructured":"Manzano GS, Woods JK, Amato AA. Covid-19-associated myopathy caused by type I interferonopathy. N Engl J Med. 2020, 383:2389-90. 10.1056\/NEJMc2031085","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2021-139725","article-title":"Myositis due to COVID-19","volume":"97","author":"Uslu S","year":"2021","unstructured":"Uslu S. Myositis due to COVID-19. Postgrad Med J. 2021, 97:399. 10.1136\/postgradmedj-2021-139725","journal-title":"Postgrad Med J"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3981","article-title":"SARS-CoV-2 infection complicated with cold agglutinin disease and myositis","volume":"9","author":"Aldaghlawi F","year":"2021","unstructured":"Aldaghlawi F, Shammah A, Kio E. SARS-CoV-2 infection complicated with cold agglutinin disease and myositis. Clin Case Rep. 2021, 9:2196-9. 10.1002\/ccr3.3981","journal-title":"Clin Case Rep"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.931570","article-title":"A 7-year-old boy and a 14-year-old girl initially diagnosed with toxic shock syndrome and tested positive for sars-cov-2 infection, supporting a diagnosis of multisystem inflammatory syndrome in children (MIS-C)","volume":"22","author":"Giordano S","year":"2021","unstructured":"Giordano S, Failla MC, Li Cavoli MG, et al.. A 7-year-old boy and a 14-year-old girl initially diagnosed with toxic shock syndrome and tested positive for sars-cov-2 infection, supporting a diagnosis of multisystem inflammatory syndrome in children (MIS-C). Am J Case Rep. 2021, 22:e931570. 10.12659\/AJCR.931570","journal-title":"Am J Case Rep"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytaa370","article-title":"Myopericarditis and myositis in a patient with COVID-19: a case report","volume":"4","author":"Shabbir A","year":"2020","unstructured":"Shabbir A, Camm CF, Elkington A, Tilling L, Stirrup J, Chan A, Bull S. Myopericarditis and myositis in a patient with COVID-19: a case report. Eur Heart J Case Rep. 2020, 4:1-6. 10.1093\/ehjcr\/ytaa370","journal-title":"Eur Heart J Case Rep"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1186\/s13395-021-00266-5","article-title":"Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature","volume":"11","author":"Islam B","year":"2021","unstructured":"Islam B, Ahmed M, Islam Z, Begum SM. Severe acute myopathy following SARS-CoV-2 infection: a case report and review of recent literature. Skelet Muscle. 2021, 11:10. 10.1186\/s13395-021-00266-5","journal-title":"Skelet Muscle"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-021-01119-y\u00a0","article-title":"Onset and relapse of juvenile dermatomyositis following asymptomatic sars-cov-2 infection","volume":"42","author":"Rodero MP","year":"2022","unstructured":"Rodero MP, Pelleau S, Welfringer-Morin A, et al.. Onset and relapse of juvenile dermatomyositis following asymptomatic sars-cov-2 infection. J Clin Immunol. 2022, 42:25-7. 10.1007\/s10875-021-01119-y\u00a0","journal-title":"J Clin Immunol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.04.036","article-title":"Dermatomyositis in a COVID-19 positive patient","volume":"13","author":"Ho BV","year":"2021","unstructured":"Ho BV, Seger EW, Kollmann K, Rajpara A. Dermatomyositis in a COVID-19 positive patient. JAAD Case Rep. 2021, 13:97-9. 10.1016\/j.jdcr.2021.04.036","journal-title":"JAAD Case Rep"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.4931","article-title":"Dermatomyositis-lupus overlap syndrome complicated with cardiomyopathy after SARS-CoV-2 infection: a new potential trigger for musculoskeletal autoimmune disease development","volume":"9","author":"Shahidi Dadras M","year":"2021","unstructured":"Shahidi Dadras M, Rakhshan A, Ahmadzadeh A, Hosseini SA, Diab R, Safari Giv T, Abdollahimajd F. Dermatomyositis-lupus overlap syndrome complicated with cardiomyopathy after SARS-CoV-2 infection: a new potential trigger for musculoskeletal autoimmune disease development. Clin Case Rep. 2021, 9:e04931. 10.1002\/ccr3.4931","journal-title":"Clin Case Rep"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.mjafi.2020.10.015","article-title":"Myositis in a patient with coronavirus disease 2019: a rare presentation","volume":"77","author":"Gupta S","year":"2021","unstructured":"Gupta S, Dixit PK, Prasad AS. Myositis in a patient with coronavirus disease 2019: a rare presentation. Med J Armed Forces India. 2021, 77:S486-9. 10.1016\/j.mjafi.2020.10.015","journal-title":"Med J Armed Forces India"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2021.05.019","article-title":"Diagnostic role of technitium-99m bone scan in severe COVID-19-associated myositis","volume":"16","author":"Hookey G","year":"2021","unstructured":"Hookey G, Ahmad Q, McCune T, Kowalewska J, Amaker B, Inayat N. Diagnostic role of technitium-99m bone scan in severe COVID-19-associated myositis. Radiol Case Rep. 2021, 16:2123-8. 10.1016\/j.radcr.2021.05.019","journal-title":"Radiol Case Rep"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-239457","article-title":"COVID-19 IgG-related autoimmune inflammatory necrotizing myositis","volume":"14","author":"Veyseh M","year":"2021","unstructured":"Veyseh M, Koyoda S, Ayesha B. COVID-19 IgG-related autoimmune inflammatory necrotizing myositis. BMJ Case Rep. 2021, 14:10.1136\/bcr-2020-239457","journal-title":"BMJ Case Rep"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1080\/20009666.2021.1878601","article-title":"Acute viral myositis complicated by rhabdomyolysis: a sole manifestation of COVID-19 infection","volume":"11","author":"Mughal MS","year":"2021","unstructured":"Mughal MS, Kaur IP, Alhashemi R, Rehman R, Du D. Acute viral myositis complicated by rhabdomyolysis: a sole manifestation of COVID-19 infection. J Community Hosp Intern Med Perspect. 2021, 11:289-91. 10.1080\/20009666.2021.1878601","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004088","article-title":"Post-covid-19 unusual inflammatory syndromes detected on 18F-FDG PET\/CT scan","volume":"47","author":"Pereira M","year":"2022","unstructured":"Pereira M, Shivdasani D, Roy D, Rungta R, Dang S, Singh N. Post-covid-19 unusual inflammatory syndromes detected on 18F-FDG PET\/CT scan. Clin Nucl Med. 2022, 47:e363-5. 10.1097\/RLU.0000000000004088","journal-title":"Clin Nucl Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/112029-prevalence-of-myositis-specific-autoantibodies-and-myositis-associated-autoantibodies-in-covid-19-patients-a-pilot-study-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:52Z","timestamp":1707507652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/112029-prevalence-of-myositis-specific-autoantibodies-and-myositis-associated-autoantibodies-in-covid-19-patients-a-pilot-study-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":54,"URL":"https:\/\/doi.org\/10.7759\/cureus.29752","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}